Peptide questions · PEG-MGF

PEG-MGF side effects: what studies and users report

Reviewed Evidence: EmergingPublished by PepVault

The side effects most commonly reported for PEG-MGF are injection site reaction, local soreness and generally little felt; its research is mostly in animals and cells, so reports in people come from community use.

Its safety note opens: No human study of MGF or PEG-MGF has been published — no trial, no pharmacokinetics, no toxicology — so there is no human safety record to report, favorable or otherwise.

What is commonly reported with PEG-MGF

  • Injection site reaction
  • Local soreness
  • Generally little felt

Common here means the library lists it among the effects people most often report; the list doesn’t say how often each one happens.

Each effect, and the other growth hormone compounds the library lists it for
EffectAlso listed for (of 13)
Injection site reaction4: Sermorelin, Tesamorelin, IGF-1 LR3, Follistatin-344
Local sorenessNone: listed for PEG-MGF alone
Generally little feltNone: listed for PEG-MGF alone
A smiling man in a grey t-shirt in his living room, holding his phone

PepVault for iPhone

Track PEG-MGF in PepVault

Log each dose and any side effect beside it, so you can see what changed and when.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Which PEG-MGF side effects the growth hormone group shares

Across the 14 growth hormone compounds in the library, the effects listed most often are water retention (10 of 14), headache (5 of 14), injection site reaction (5 of 14) and fatigue (4 of 14). PEG-MGF shares 1 of its 3 listed effects with at least one other growth hormone compound; local soreness and generally little felt are listed for PEG-MGF alone.

What the PEG-MGF safety notes say

The library’s safety note

No human study of MGF or PEG-MGF has been published — no trial, no pharmacokinetics, no toxicology — so there is no human safety record to report, favorable or otherwise. What is known cuts both ways. The animal work used synthetic versions of the peptide (one study a chemically stabilized analogue), delivered locally, often into heart muscle, and reported no harm within those experiments. Against that, the same E-domain peptide is the part of IGF-1Ec that research links to tumor biology: IGF-1Ec expression is raised in prostate cancer, where it tracks tumor stage, and in more advanced papillary thyroid cancer, and is altered in colorectal and bladder tumors, and the peptide itself behaved as an autonomous growth signal in prostate cancer cells; a 2026 clinical review flags that as a biologically plausible, unproven concern rather than an observed harm in users. Product identity is a real issue: the MGF preparations seized from the market were C-terminally amidated analogues rather than the human sequence, another confiscated vial held a variant called MGF R23H, and in one survey of products sold as follistatin, MGF turned up as the actual contents. For athletes: mechano growth factors are named and prohibited at all times under the 2026 WADA list (S2.3). Discuss with your clinician; this is an unapproved research compound with no human data behind it.

The library’s interaction note

No interaction data of any kind exists for MGF or PEG-MGF, in people or animals. Mechanistically it sits on the IGF-1 arm, so it is commonly run with GH, GH secretagogues or IGF-1 LR3, and none of those combinations has been studied; unlike IGF-1 itself, the E-domain peptide is not known to lower blood glucose, and no study has looked. Discuss any prescription medications with your clinician.

These are reference notes from published research and reported use, not advice for a person: discuss your own situation with your clinician.

Where the PEG-MGF reports come from

The library rates the evidence on PEG-MGF as emerging: mostly preclinical, with limited human data.

Of the library’s 7 research notes on PEG-MGF, 5 rest on animal studies and 2 on community reports.

Our 4 study pages on PEG-MGF: 1 cell study (C2C12 cells, primary human skeletal muscle myoblasts, primary mouse skeletal muscle stem cells and cardiac myocytes), 1 animal study (mice), 1 cell study (human muscle cells) and 1 cell study (human prostate cancer cells).

So the effects listed for PEG-MGF come from people who have used it, not from a controlled trial in people.

Questions people ask

What are the side effects of PEG-MGF?

The side effects most commonly reported for PEG-MGF are injection site reaction, local soreness and generally little felt; its research is mostly in animals and cells, so reports in people come from community use.

Do PEG-MGF’s side effects come from human studies?

The library rates the evidence on PEG-MGF as emerging, and its research is mostly in animals and cells, so reports in people come from community use.

Which PEG-MGF side effects are its own?

Among the growth hormone compounds, the library lists local soreness and generally little felt for PEG-MGF alone.

Does PEG-MGF interact with other medicines?

The library’s interaction note on PEG-MGF begins: No interaction data of any kind exists for MGF or PEG-MGF, in people or animals.

More on PEG-MGF

Track it in the app

PepVault for iPhone

Track PEG-MGF in PepVault

Log each dose and any side effect beside it, so you can see what changed and when.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo